GlycoMimetics Files 8-K for Financials and Exhibits

Ticker: CBIO · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1253689

Glycomimetics INC 8-K Filing Summary
FieldDetail
CompanyGlycomimetics INC (CBIO)
Form Type8-K
Filed DateMar 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financials, reporting

Related Tickers: GLYC

TL;DR

GlycoMimetics filed a routine 8-K on March 1st for financials, no major news.

AI Summary

GlycoMimetics, Inc. filed an 8-K on March 1, 2024, reporting on its financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.

Why It Matters

This filing serves as a standard update for investors regarding GlycoMimetics' financial reporting and exhibits, without disclosing new material information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, indicating no new material events or significant risks have been disclosed.

Key Players & Entities

FAQ

What is the purpose of this Form 8-K filing by GlycoMimetics, Inc.?

The Form 8-K is filed to report on Financial Statements and Exhibits, and for Regulation FD Disclosure.

When was this Form 8-K filed?

The filing was made on March 1, 2024.

What is the principal executive office address for GlycoMimetics, Inc.?

The address is 9708 Medical Center Drive, Rockville, MD 20850.

What is the telephone number for GlycoMimetics, Inc.?

The telephone number is (240) 243-1201.

Does this filing indicate any changes in GlycoMimetics, Inc.'s former name or address?

The filing states 'N/A' for former name or former address, indicating no changes since the last report.

Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-01 09:16:05

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. A copy of a slide presentation that GlycoMimetics, Inc. (the "Company") plans to use for anticipated investor meetings is attached to this Current Report as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

01. Exhibits

Item 9.01. Exhibits. (d) Exhibits 9, Exhibit Number Exhibit Description 99.1 GlycoMimetics, Inc. Corporate Presentation, March 1, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLYCOMIMETICS, INC. By: /s/ Brian M. Hahn Date: March 1, 2024 Brian M. Hahn Senior Vice President and Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing